Last reviewed · How we verify
induction chemotherapy
Induction chemotherapy involves administering high-dose chemotherapy to kill cancer cells before a main treatment, such as surgery or radiation.
Induction chemotherapy involves administering high-dose chemotherapy to kill cancer cells before a main treatment, such as surgery or radiation. Used for Treatment of various cancers, including but not limited to breast cancer, lung cancer, and lymphoma.
At a glance
| Generic name | induction chemotherapy |
|---|---|
| Also known as | IC, Fludara, Endoxan, Cytoxan, Neosar, Procytox, Revimmune, cytophosphane, 7+3, Ara-C |
| Sponsor | Zhejiang Cancer Hospital |
| Drug class | Chemotherapeutic agent |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This approach is used to reduce tumor size and make it easier to remove or treat. The specific chemotherapy agents used can vary depending on the type and stage of cancer.
Approved indications
- Treatment of various cancers, including but not limited to breast cancer, lung cancer, and lymphoma
Common side effects
- Nausea and vomiting
- Fatigue
- Hair loss
- Infection
- Anemia
Key clinical trials
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
- Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer (PHASE2)
- Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN) (PHASE2)
- Durvalumab as Consolidation for Patients LS-SCLC (PHASE2)
- Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |